semaglutide .75 mg release injectable medication containing semaglutide Wegovy® | Wegovy Weight Loss

Semaglutide has become well known for helping patients reduce appetite and achieve steady weight loss over time

The combination: CagriSema explained CagriSema is the fixed-dose co-formulation of cagrilintide 2.4mg and semaglutide 2.4mg developed by Novo Nordisk, delivered as a single once-weekly subcutaneous injection

In March 2024, Viking Therapeutics announced positive results from the company's Phase I multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735 , a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development for the potential treatment of metabolic disorders such as obesity

For Wegovy specifically, patients can report pregnancy exposure to the manufacturer's pregnancy registry, which collects information about outcomes of pregnancies exposed to the medication